Sequential chemotherapy and icotinib as first-line treatment for advanced epidermal growth factor receptor-mutated non-small cell lung cancer

doi:10.12998/wjcc.v10.i18.6069

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 18

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3417)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-4) series.

Item

Count

PDF

164

WORD

HTML

1520

Figures (1-3)

413

Tables (1-4)

312

Sum=2476

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

284

Download

657

Sum=941

Jun 26, 2022 (publication date) through Nov 18, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Randomized Controlled Trial

World J Clin Cases. Jun 26, 2022; 10(18): 6069-6081
Published online Jun 26, 2022. doi: 10.12998/wjcc.v10.i18.6069

Full Size Figure Download Figure

Figure 2 Progression-free survival of patients. A: Progression-free survival (PFS) with icotinib vs chemotherapy followed by icotinib; B: PFS with two-cycle chemotherapy followed by icotinib vs four-cycle chemotherapy followed by icotinib; C: PFS with DP followed by icotinib vs PP followed by icotinib; D: PFS with icotinib vs various chemotherapy regimens followed by icotinib. DP: Docetaxel/cisplatin; PP: Pemetrexed/cisplatin.

Citation: Sun SJ, Han JD, Liu W, Wu ZY, Zhao X, Yan X, Jiao SC, Fang J. Sequential chemotherapy and icotinib as first-line treatment for advanced epidermal growth factor receptor-mutated non-small cell lung cancer. World J Clin Cases 2022; 10(18): 6069-6081
URL: https://www.wjgnet.com/2307-8960/full/v10/i18/6069.htm
DOI: https://dx.doi.org/10.12998/wjcc.v10.i18.6069